Clinical Trial Results:
An Open-Label, Multi-Centre, Randomised Parallel Group Comparison of Efficacy and Safety of Degarelix Three-Month Depot in Three Different Dosing Regimens of 240 mg (40 mg/mL) and 240 mg (60 mg/mL) in Patients with Prostate Cancer Requiring Androgen Ablation Therapy
Summary
|
|
EudraCT number |
2004-003815-22 |
Trial protocol |
FI GB |
Global completion date |
08 Nov 2006
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
02 Feb 2016
|
First version publication date |
28 May 2015
|
Other versions |
|
Summary report(s) |
FE 200486 CS15 summary report |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.